Completed PHASE2 INTERVENTIONAL 1-arm NCT00325507

Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal Cell Carcinoma

Safety, Immunology, and Biological Activity Evaluation of TroVax® in Treatment of Patients With Locally Advanced or Metastatic Renal Carcinoma

Sponsor: ORION Clinical Services

Conditions Carcinoma, Renal Cell

Interventions IL-2 TroVax

Updated 9 times since 2017 Last updated: Oct 9, 2020 Started: Nov 30, 2005 Primary completion: Jul 31, 2008 Completion: Jul 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Carcinoma, Renal Cell, this trial is completed. The trial is conducted by ORION Clinical Services and has accumulated 9 data snapshots since 2005. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE2
Oct 2021 — Apr 2022 [monthly]

Completed PHASE2
Jan 2021 — Oct 2021 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Nov 2020 — Jan 2021 [monthly]

Completed PHASE2
Oct 2020 — Nov 2020 [monthly]

Completed PHASE2
Jun 2018 — Oct 2020 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Nov 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ORION Clinical Services
Oxford BioMedica
The Methodist Hospital Research Institute

Data source: Oxford BioMedica

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States